Device closure of patent foramen ovale in cryptogenic stroke: Still stuck in hamlet mode

2013 ◽  
Vol 84 (1) ◽  
pp. 167-167
Author(s):  
Abdur Rahman Khan ◽  
Aref Bin Abdulhak ◽  
Ehab A. Eltahawy
Keyword(s):  
Patent Foramen Ovale ◽  
Cryptogenic Stroke ◽  
Foramen Ovale ◽  
Device Closure

scholarly journals Comparison of Outcomes after Device Closure and Medication Alone in Patients with Patent Foramen Ovale and Cryptogenic Stroke in Korean Population

2016 ◽  
Vol 57 (3) ◽  
pp. 621 ◽  
Author(s):  
Jeonggeun Moon ◽  
Woong Chol Kang ◽  
Sihoon Kim ◽  
Pyung Chun Oh ◽  
Yae Min Park ◽  
...  
Keyword(s):  
Patent Foramen Ovale ◽  
Cryptogenic Stroke ◽  
Korean Population ◽  
Foramen Ovale ◽  
Device Closure

scholarly journals The role of device closure of patent foramen ovale in patients with cryptogenic stroke

2020 ◽  
Vol 288 (4) ◽  
pp. 400-409
Author(s):  
M. Fukutomi ◽  
B. Wilkins ◽  
L. Søndergaard
Keyword(s):  
Patent Foramen Ovale ◽  
Cryptogenic Stroke ◽  
Foramen Ovale ◽  
Device Closure

scholarly journals Device Closure of Patent Foramen Ovale in Patients With Cryptogenic Stroke

2018 ◽  
Vol 71 (20) ◽  
pp. 2343-2345 ◽  
Author(s):  
Dmitriy N. Feldman ◽  
Jesse Weinberger ◽  
Sammy Elmariah
Keyword(s):  
Patent Foramen Ovale ◽  
Cryptogenic Stroke ◽  
Foramen Ovale ◽  
Device Closure

scholarly journals Recurrent Stroke/TIA in Cryptogenic Stroke Patients with Patent Foramen Ovale

2007 ◽  
Vol 34 (1) ◽  
pp. 74-80 ◽  
Author(s):  
Leanne Casaubon ◽  
Peter McLaughlin ◽  
Gary Webb ◽  
Erik Yeo ◽  
Darren Merker ◽  
...  
Keyword(s):  
Patent Foramen Ovale ◽  
Recurrent Events ◽  
Recurrent Stroke ◽  
Cryptogenic Stroke ◽  
Antiplatelet Agents ◽  
Secondary Outcome ◽  
Foramen Ovale ◽  
Device Closure ◽  
Surgical Closure ◽  
Significant Difference

Background:Patent foramen ovale (PFO) is present in 40% of patients with cryptogenic stroke and may be associated with paradoxical emboli to the brain. Therapeutic options include antiplatelet agents, anticoagulation, percutaneous device and surgical closure. We assessed the hypothesis that there are differences in rates of recurrent TIA or stroke between patients in the four treatment groups.Methods:Patients presenting from January 1997 with cryptogenic stroke or TIA and PFO were followed prospectively until June 2003. Treatment choice was made on an individual case basis. The primary outcome was recurrent stroke. The secondary outcome was a composite of stroke, TIA, and vascular death.Results:Baseline. Our cohort consisted of 121 patients; 64 (53%) were men. Median age was 43 years. Sixty-nine percent presented with stroke and 31% with TIA. One or more vascular risk factor was present in 40%. Atrial septal aneurysm (ASA) was present in 24%. Treatment consisted of antiplatelet agents (34%), anticoagulation (17%), device (39%) and surgical closure (11%). Follow-up. Recurrent events occurred in 16 patients (9 antiplatelet, 3 anticoagulation, 4 device closure); 7 were strokes, 9 were TIA. Comparing individual treatments there was a trend toward more strokes in the antiplatelet arm (p=0.072); a significant difference was seen for the composite endpoint (p=0.012). Comparing closure versus combined medical therapy groups, a significant difference was seen for primary (p=0.014) and secondary (p=0.008) outcomes, favoring closure. Age and pre-study event predicted outcome.Conclusion:Patent foramen ovale closure was associated with fewer recurrent events. Complications of surgical and device closure were self-limited.

Sign in / Sign up

Export Citation Format

Share Document